Initiator Pharma A/S (SE:INIT)
:INIT
Want to see SE:INIT full AI Analyst Report?
INIT Stock Chart & Stats
kr3.04
-kr0.20(-3.17%)
At close: 4:00 PM EST
kr3.04
-kr0.20(-3.17%)
Day’s Range― - ―
52-Week Rangekr2.53 - kr4.17
Previous CloseN/A
Volume47.38K
Average Volume (3M)133.41K
Market Cap
kr180.72M
Enterprise Valuekr129.58M
Total Cash (Recent Filing)kr19.90M
Total Debt (Recent Filing)kr7.56M
Price to Earnings (P/E)―
Beta0.61
Next Earnings
Aug 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.33
Shares Outstanding68,452,890
10 Day Avg. Volume157,519
30 Day Avg. Volume133,406
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)4.31
Price to Sales (P/S)0.00
P/FCF Ratio-7.18
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.31
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Focused Pipeline In Sexual & Reproductive HealthA concentrated R&D focus on sexual and reproductive health creates durable competitive advantage through deep domain expertise and targeted development. This specialization can improve trial design efficiency, attract strategic partners for later-stage commercialization, and align resources to high-unmet-need niches.
Modest Leverage And Positive EquityLow debt relative to equity preserves financial flexibility for a pre-revenue biotech, reducing immediate solvency pressure. Positive equity and modest leverage support the ability to raise non-distressed capital or enter partnerships without urgent balance-sheet constraints, lengthening runway options.
Lean Operating StructureA very small headcount limits fixed overhead and can extend cash runway compared with larger peers, enabling more efficient allocation to clinical spend. For a virtual or asset-focused biotech, lean operations facilitate flexible outsourcing and lower burn per development milestone.
Bears Say
No Revenue And Widening LossesPersistent pre-revenue status and materially widening losses signal extended development timelines and escalating funding needs. Continued negative profitability reduces retained capital and increases reliance on external financing, which may dilute shareholders and stress strategic optionality over months.
Consistent Negative Operating Cash FlowSustained cash burn at material levels necessitates recurrent funding events to maintain operations and progress trials. Regular capital raises can dilute ownership, divert management attention to financing, and introduce execution risk if markets or partner interest weaken when trials need resources.
Equity Decline Raises Dilution RiskA falling equity base reflects cumulative losses and prior funding dilution, reducing cushion for future write-downs. As equity erodes, the company faces greater pressure to secure funds on dilutive terms or via partnerships, which can limit upside for existing investors and constrain long-term strategic choices.
INIT FAQ
What was Initiator Pharma A/S’s price range in the past 12 months?
Initiator Pharma A/S lowest stock price was kr2.53 and its highest was kr4.17 in the past 12 months.
What is Initiator Pharma A/S’s market cap?
Initiator Pharma A/S’s market cap is kr180.72M.
When is Initiator Pharma A/S’s upcoming earnings report date?
Initiator Pharma A/S’s upcoming earnings report date is Aug 21, 2026 which is in 67 days.
How were Initiator Pharma A/S’s earnings last quarter?
Initiator Pharma A/S released its earnings results on May 08, 2026. The company reported -kr0.242 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.242.
Is Initiator Pharma A/S overvalued?
According to Wall Street analysts Initiator Pharma A/S’s price is currently Overvalued.
Does Initiator Pharma A/S pay dividends?
Initiator Pharma A/S does not currently pay dividends.
What is Initiator Pharma A/S’s EPS estimate?
Initiator Pharma A/S’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Initiator Pharma A/S have?
Initiator Pharma A/S has 68,452,890 shares outstanding.
What happened to Initiator Pharma A/S’s price movement after its last earnings report?
Initiator Pharma A/S reported an EPS of -kr0.242 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.297%.
Which hedge fund is a major shareholder of Initiator Pharma A/S?
Currently, no hedge funds are holding shares in SE:INIT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Initiator Pharma A/S
Initiator Pharma A/S is a clinical-stage life sciences firm dedicated to discovering therapeutic solutions for critical unmet medical needs affecting the central and peripheral nervous systems. Its development pipeline features several clinical-phase compounds: IP2018, a monoamine reuptake inhibitor aimed at psychogenic erectile dysfunction; IPED2015, designed to address organic erectile dysfunction; and IPTN2021, an orphan drug candidate for severe neuropathic pain. Additionally, the company holds early-stage assets, including IPNP2015 for chronic pain management and IPDP2015 for depression. Established in 2016, Initiator Pharma A/S maintains its headquarters in Copenhagen, Denmark.